Loading...
•
Sep 30, 2024
Harmony Biosciences Q3 2024 Earnings Report
Harmony Biosciences reported strong financial results in the third quarter of 2024, driven by WAKIX sales and pipeline advancements.
Key Takeaways
Harmony Biosciences reported a record $186.0 million in net revenue for Q3 2024. The company is on track to submit an sNDA for pitolisant in Idiopathic Hypersomnia in Q4 2024. They reiterated their 2024 net product revenue guidance of $700 - $720 million.
Net product revenues for the quarter were $186.0 million, compared to $160.3 million for the same period in 2023.
GAAP net income for the quarter was $46.1 million, or $0.79 earnings per diluted share.
Non-GAAP adjusted net income was $59.6 million, or $1.03 earnings per diluted share.
Harmony had cash, cash equivalents and investments of $504.7 million as of September 30, 2024.
Revenue by Segment
Forward Guidance
Harmony Biosciences expects full year 2024 net product revenue of $700 million to $720 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...